The increasing availability of devices capable of tracking biomarkers presents major opportunities in contemporary healthcare. Herein we advocate a new role for the pharmaceutical industry to capitalize on these opportunities and, in doing so, incorporate wellness and patient engagement programs into their standard business models. Medical-grade decision-making using diagnostic, prognostic, and monitoring biomarkers will require coordinated approaches between the pharmaceutical and technology industries and the careful design of longitudinal clinical studies to validate their efficacy. These studies will also require data capture, archiving, curating, and sharing on a previously unprecedented scale, and raise additional concerns with regard to data security and ownership. Concurrently, systems-based approaches to the capture and interpretation of a new class of digital biomarkers are emerging, and they hold promise for heightened levels of patient engagement and remote sensing. Collectively, if these new opportunities are approached within the context of the patient-provider ecosystem, major repositioning of the pharmaceutical industry may be possible in the near future.

中文翻译：

---

利用数字废气：将健康纳入制药模式


能够跟踪生物标志物的设备的不断增加为当代医疗保健带来了重大机遇。在此，我们倡导制药行业发挥新作用，利用这些机会，并将健康和患者参与计划纳入其标准商业模式。使用诊断、预后和监测生物标志物进行医疗级决策需要制药和技术行业之间采取协调一致的方法，并仔细设计纵向临床研究以验证其功效。这些研究还需要以前所未有的规模进行数据采集、归档、整理和共享，并引发对数据安全和所有权的额外担忧。与此同时，基于系统的捕获和解释新型数字生物标志物的方法正在出现，它们有望提高患者参与和遥感水平。总的来说，如果在患者-提供者生态系统的背景下抓住这些新机遇，制药行业可能在不久的将来进行重大重新定位。